346577-65-9 Usage
Indolinone derivative
A synthetic chemical compound This refers to the structure and classification of the compound, which is derived from the indolinone core structure.
Pharmaceutical properties
Anti-inflammatory and antiproliferative agent These are the potential therapeutic effects of 1-benzyl-5-ethoxy-2-indolinone, which have been studied in preclinical research.
Inhibiting cancer cell growth
Promising effects The compound has shown potential in slowing down or stopping the growth of cancer cells in preclinical studies.
Reducing inflammation
Preclinical studies The compound has demonstrated its ability to reduce inflammation in early research, which could be beneficial in treating inflammatory conditions.
Treatment of neurodegenerative diseases
Potential use 1-benzyl-5-ethoxy-2-indolinone has been investigated for its possible application in treating diseases that affect the nervous system, such as Alzheimer's or Parkinson's.
Therapeutic agent
Biomedical applications The compound holds promise as a treatment for various medical conditions, making it a valuable candidate for further research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 346577-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,6,5,7 and 7 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 346577-65:
(8*3)+(7*4)+(6*6)+(5*5)+(4*7)+(3*7)+(2*6)+(1*5)=179
179 % 10 = 9
So 346577-65-9 is a valid CAS Registry Number.
346577-65-9Relevant academic research and scientific papers
Total synthesis of SR 121463 A, a highly potent and selective vasopressin V2 receptor antagonist
Venkatesan,Davis,Altas,Snyder,Liotta
, p. 3653 - 3661 (2007/10/03)
SR 121463 A, 1, is a promising nonpeptide prototype for potent and selective antagonism of the vasopressin V2 receptor subtype and, thus, a candidate for control of the clinically debilitating condition of hyponatremia and its associated syndromes. In the present work, we present a novel and stereoselective synthesis that stems from the preparation of three key intermediates: the substituted benzenesulfonyl chloride 2, the N-protected oxindole 3, and protected dibromide 4. The synthesis of 1 has been achieved in good overall yield, each step proceeding in greater than 80% yield. In addition, intermediate 2 and the syn isomer of 1 were prepared with complete control of stereochemistry. The latter reduction appears to proceed by lithium cation mediated chelation control. Molecular mechanics calculations with the MM3* and MMFF force fields underscore geometric and energetic aspects of the reaction.
